Therapeutic Bacterial Composition for Ulcerative Colitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis (UC) and Crohn's Disease (CD) often have severe side-effects and variable responses due to their inability to account for the microbiome's role in disease pathology, leading to a need for more effective therapeutic methods.
Innovation Solution
A composition comprising specific bacterial species, identified by their 16S rDNA sequences, which are capable of colonizing the gastrointestinal tract and inducing clinical remission in UC and CD patients, either alone or in combination, providing a defined and standardized treatment alternative to faecal microbiota transplants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immune modulation therapies are used to treat UC and CD, then disease symptoms can be suppressed, but severe side effects occur and treatment response varies
Solution Approach 1:
The invention extracts and isolates specific beneficial bacterial species from complex microbiota sources. Instead of using broad-spectrum immune modulators that affect the entire immune system, the patent identifies and applies only the specific bacterial species (such as those from FMT treatments) that directly address the microbiome deficiency, thereby avoiding the severe side effects of systemic immune suppression while maintaining effective treatment of UC and CD
Solution Approach 2:
The invention changes the fundamental treatment parameter from immune system modulation to microbiome restoration. By shifting the therapeutic approach from modifying immune response parameters to restoring microbial community composition parameters, the treatment achieves disease control through a different biological pathway that avoids immune-related side effects while improving response consistency
2Reliability
If FMT is used to treat UC and CD, then clinical remission can be induced, but the treatment lacks standardization and defined composition
Solution Approach 1:
The invention segments the complex FMT treatment into its individual functional bacterial components. Instead of administering undifferentiated stool material, the patent isolates and defines specific bacterial species and strains that contribute to therapeutic effect, enabling each component to be independently characterized, standardized, and controlled for consistent clinical outcomes
Solution Approach 2:
The invention creates a standardized composite bacterial product comprising multiple specific bacterial species in defined proportions. This composite formulation combines the therapeutic benefits of various beneficial bacteria while maintaining consistent composition across batches, thereby achieving both the clinical efficacy of FMT and the manufacturing precision required for regulated therapeutic use
Data Source
AI summary
The disclosure relates to therapeutic compositions comprising isolated bacteria useful in the treatment of ulcerative colitis or Crohn's disease. Related methods and uses are also disclosed.